Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
Pharmacokinetic properties and metabolism of idebenone.
Study hints of rituximab MS benefit
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Genetics of multiple sclerosis: swimming in an ocean of data.
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.
Mitoxantrone for multiple sclerosis.
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons.
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain.
Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis.
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
Role of the Blood-Brain Barrier in Multiple Sclerosis.

Pages